A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe HS
Latest Information Update: 05 May 2023
At a glance
- Drugs Zunsemetinib (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Sponsors Aclaris Therapeutics
- 02 May 2023 According to Aclaris Therapeutics media release, Management will conduct a conference call at 8:00 AM ET on 2 May to discuss summary of final results from this trial. The conference call will be webcast live over the internet and can be accessed by logging into the the Investors page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. The webcast will be archived for at least 30 days on the Aclaris website.
- 31 Mar 2023 Status changed from active, no longer recruiting to completed.
- 06 Mar 2023 Primary endpoint (Efficacy measured as the change from Baseline in inflammatory nodule/abscess count at Week 12 moderate to severe HS.) has not been met as per results published in the Aclaris Therapeutics Media Release